BCL2 and neoplasm: HetIL-15, a fusion protein composed of IL-15 and IL-15Rα, has demonstrated efficacy in preclinical studies, slowing tumor growth, increasing tumor infiltration of NK cells and CD8+ T cells, and promoting IFN-γ production, cytotoxic particles, and anti-apoptosis protein B-cell lymphoma-2(BCL-2) expression (111).